首页|期刊导航|辽宁中医药大学学报|六君子汤调节肠道屏障、炎症反应和肠道菌群改善肌少症机制研究

六君子汤调节肠道屏障、炎症反应和肠道菌群改善肌少症机制研究OA

Research on the Mechanism of Liujunzi Decoction(六君子汤)in Regulating Intestinal Barrier,Inflammation and Gut Microbiota to Improve Sarcopenia

中文摘要英文摘要

胃癌(gastric cancer,GC)是发病率与病死率较高的恶性肿瘤,肌少症作为其常见并发症,严重影响患者生活质量与预后.西医治疗依赖营养支持等手段,难以根治代谢紊乱,而肠道屏障紊乱、慢性炎症及菌群失调是肌少症的重要诱因,中医药在整体调节机体功能方面具有独特优势.为探究六君子汤通过调节肠道屏障功能、炎症反应及肠道菌群,改善GC相关肌少症的作用机制,为临床治疗提供理论依据,该文通过查阅国内外相关文献,系统总结六君子汤对肠道屏障(紧密连接蛋白、上皮修复)、炎症反应(炎症因子、信号通路)、肠道菌群(结构、代谢产物)的调控作用,同时分析其在GC患者中的临床应用效果与安全性.结果发现,六君子汤可上调紧密连接蛋白[闭锁小带蛋白-1(zonula occludens-1,ZO-1)、闭合蛋白(Occludin)]表达、促进肠道上皮修复,增强肠道屏障完整性;通过抑制促炎因子[肿瘤坏死因子-α(tumor necrosis factor-α,TNF-α)、白细胞介素-1β(interleukin-1β,IL-1β)等]、激活抗炎因子、调控核因子κB(nuclear factor kappa-B,NF-κB)/丝裂原活化蛋白激酶(mitogen-activated protein kinase,MAPK)/p38丝裂原活化蛋白激酶(p38 mitogen-activated protein kinase,p38 MAPK)等信号通路减轻炎症反应;还能优化肠道菌群结构、增加短链脂肪酸(short-chain fatty acids,SCFAs)等有益代谢产物,改善肠道微生态;临床应用中可缓解GC患者恶心、食欲不振等症状,提高生活质量,且安全性较高.六君子汤通过多途径协同作用改善GC相关肌少症,具有重要临床价值,但当前研究仍存在分子机制未完全阐明、缺乏大规模多中心临床试验等局限,未来需进一步深化机制研究与规范临床设计.

Gastric cancer(GC)is a malignant tumor with high incidence and mortality,and sarcopenia,its common complication,severely impairs patients'quality of life and prognosis.Western medical treatments,mainly relying on nutritional support,hardly eliminate metabolic disorders fundamentally;meanwhile,intestinal barrier dysfunction,chronic inflammation,and gut microbiota dysbiosis are key triggers of sarcopenia,and traditional Chinese medicine(TCM)has unique advantages in holistic regulation of bodily functions.To explore the mechanism by which Liujunzi Decoction(六君子汤)ameliorates GC-related sarcopenia by regulating intestinal barrier function,inflammatory responses,and gut microbiota,and provide a theoretical basis for clinical practice,this study systematically summarized Liujunzi Decoction's regulatory effects on intestinal barrier(tight junction proteins,epithelial repair),inflammatory responses(inflammatory factors,signaling pathways),and gut microbiota(structure,metabolites),as well as analyzed its clinical efficacy and safety in GC patients by reviewing relevant domestic and international literature.The results showed that Liujunzi Decoction enhances intestinal barrier integrity by upregulating the expression of tight junction proteins[zonula occludens-1(ZO-1),Occludin]and promoting intestinal epithelial repair;alleviates inflammatory responses by inhibiting pro-inflammatory factors[tumor necrosis factor-α(TNF-α),interleukin-1β(IL-1β),etc.],activating anti-inflammatory factors,and regulating nuclear factor kappa-B(NF-κB)/mitogen-activated protein kinase(MAPK)/p38 mitogen-activated protein kinase(p38 MAPK)signaling pathways;optimizes gut microbiota structure,increases beneficial metabolites such as short-chain fatty acids(SCFAs),and improves intestinal microecology;additionally,it relieves symptoms like nausea and anorexia in GC patients,improves quality of life,and has high safety.In conclusion,Liujunzi Decoction exerts a synergistic effect through multiple pathways to ameliorate GC-related sarcopenia with significant clinical value,but current research still has limitations such as incompletely clarified molecular mechanisms and lack of large-scale multicenter clinical trials,so future studies need to further deepen mechanistic research and standardize clinical design.

王凯;张锦;郑瑾

陕西中医药大学,陕西 咸阳 712046||空军军医大学唐都医院,陕西 西安 710038空军军医大学唐都医院,陕西 西安 710038空军军医大学唐都医院,陕西 西安 710038

医药卫生

六君子汤肠道屏障炎症反应胃癌肌少症紧密连接蛋白短链脂肪酸NF-κB信号通路

Liujunzi Decoction(六君子汤)intestinal barrierinflammatory responsegastric cancersarcopeniatight junction proteinsshort-chain fatty acidsNF-κB signaling pathway

《辽宁中医药大学学报》 2026 (9)

78-84,7

陕西省重点研发计划项目(2024SF-YBXM-459)陕西省中医药管理局项目(SZY-KJCYC-2025-LC-003)陕西省自然科学基础研究计划项目(2025JC-YBMS-868)陕西省中医药管理局中医药科技创新计划项目(2025-CXRC-09)

10.13194/j.issn.1673-842X.2026.09.013

评论